Joshi Deepak Chandra, Sharma Anurag, Prasad Sonima, Singh Karishma, Kumar Mayank, Sherawat Kajal, Tuli Hardeep Singh, Gupta Madhu
Department of Pharmacy, School of Chemical Sciences and Pharmacy, Central University of Rajasthan, Bandar Sindri, Dist., Ajmer, Rajasthan, India.
Invertis Institute of Pharmacy, Invertis University Bareilly Uttar Pradesh, Bareilly, India.
Discov Oncol. 2024 Aug 11;15(1):342. doi: 10.1007/s12672-024-01195-7.
Novel therapeutic agents in clinical trials offer a paradigm shift in the approach to battling this prevalent and destructive disease, and the area of cancer therapy is on the precipice of a trans formative revolution. Despite the importance of tried-and-true cancer treatments like surgery, radiation, and chemotherapy, the disease continues to evolve and adapt, making new, more potent methods necessary. The field of cancer therapy is currently witnessing the emergence of a wide range of innovative approaches. Immunotherapy, including checkpoint inhibitors, CAR-T cell treatment, and cancer vaccines, utilizes the host's immune system to selectively target and eradicate malignant cells while minimizing harm to normal tissue. The development of targeted medicines like kinase inhibitors and monoclonal antibodies has allowed for more targeted and less harmful approaches to treating cancer. With the help of genomics and molecular profiling, "precision medicine" customizes therapies to each patient's unique genetic makeup to maximize therapeutic efficacy while minimizing unwanted side effects. Epigenetic therapies, metabolic interventions, radio-pharmaceuticals, and an increasing emphasis on combination therapy with synergistic effects further broaden the therapeutic landscape. Multiple-stage clinical trials are essential for determining the safety and efficacy of these novel drugs, allowing patients to gain access to novel treatments while also furthering scientific understanding. The future of cancer therapy is rife with promise, as the integration of artificial intelligence and big data has the potential to revolutionize early detection and prevention. Collaboration among researchers, and healthcare providers, and the active involvement of patients remain the bedrock of the ongoing battle against cancer. In conclusion, the dynamic and evolving landscape of cancer therapy provides hope for improved treatment outcomes, emphasizing a patient-centered, data-driven, and ethically grounded approach as we collectively strive towards a cancer-free world.
临床试验中的新型治疗药物为对抗这种普遍且具有破坏性的疾病提供了一种范式转变,癌症治疗领域正处于一场变革性革命的边缘。尽管手术、放疗和化疗等经过验证的癌症治疗方法很重要,但这种疾病仍在不断演变和适应,因此需要新的、更有效的方法。目前,癌症治疗领域正在见证多种创新方法的出现。免疫疗法,包括检查点抑制剂、嵌合抗原受体T细胞(CAR-T)治疗和癌症疫苗,利用宿主的免疫系统选择性地靶向并根除恶性细胞,同时将对正常组织的损害降至最低。激酶抑制剂和单克隆抗体等靶向药物的开发,使得治疗癌症的方法更具针对性且危害更小。借助基因组学和分子图谱,“精准医学”根据每位患者独特的基因构成定制治疗方案,以最大限度地提高治疗效果,同时将不良副作用降至最低。表观遗传疗法、代谢干预、放射性药物,以及对具有协同效应的联合疗法的日益重视,进一步拓宽了治疗前景。多阶段临床试验对于确定这些新药的安全性和有效性至关重要,既能让患者获得新的治疗方法,又能增进科学认识。癌症治疗的未来充满希望,因为人工智能和大数据的整合有可能彻底改变早期检测和预防。研究人员、医疗保健提供者之间的合作以及患者的积极参与仍然是当前抗癌斗争的基石。总之,癌症治疗动态且不断演变的格局为改善治疗结果带来了希望,强调在我们共同努力迈向无癌世界的过程中,要采取以患者为中心、数据驱动且符合伦理道德的方法。
Discov Oncol. 2024-8-11
Cochrane Database Syst Rev. 2018-2-6
Early Hum Dev. 2020-11
Curr Oncol Rep. 2018-2-7
Adv Exp Med Biol. 2007
Curr Treat Options Oncol. 2023-11
J Can Assoc Gastroenterol. 2019-2
Nanomaterials (Basel). 2025-5-22
Cancers (Basel). 2025-3-25
Cancers (Basel). 2025-1-8
J Clin Invest. 2024-1-16
Pharmaceuticals (Basel). 2023-11-16
Clin Chim Acta. 2023-11-1
Ann Oncol. 2023-10
Mol Psychiatry. 2023-8
Biology (Basel). 2023-7-13
Semin Cancer Biol. 2023-10
J Hematol Oncol. 2023-7-14